Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV

HIV Clinical Trials

Volumn 9, Issue 2, 2008, Pages 91-102

  Collier, Ann C ^a,x   Tierney, Camlin ^b   Downey, Gerald F ^b   Eshleman, Susan H ^c   Kashuba, Angela ^d   Klingman, Karin ^e   Vergis, Emanuel N ^f   Pakes, Gary E ^g   Rooney, James F ^h   Rinehart, Alex ⁱ   Mellors, John W ^f   Bishopric, George ⁿ   Brizz, Barbara ⁿ   Cooper, Marlene ⁿ   Gideon, Linda ⁿ   Grosskopf, Nicole ⁿ   Ha, Belinda ⁿ   Jarocki, Bernadette ⁿ   Martinez, Ana ⁿ   Reid, Jane ⁿ   Scott, Trevor ⁿ   Tustin, Nancy ⁿ   Acosta, Ed ⁿ   Astley, Merissa L ⁿ   Rodriguez, Benigno ^j   Walton, Patricia ^j   Feinberg, Judith ^k   Baer, Jenifer ^k   Mendez, Luis M ^l   Canchola, Frances ^l   Para, Michael F ^m   Laughlin, Laura ^m   Eron Jr , Joseph J ^d   Marcus, Cheryl ^d   Hughes, Valery ⁿ   Stroberg, Todd ⁿ   Hare, Brad ^o,p   Lawrence, Jody ^o,p   Skiest, Daniel J ^q   Tarbutton, Jesse ^q   O'Brien, William A ⁿ   Mogridge, Cheryl ⁿ   Cavanagh, Karen ^r,s   Gonzalez, Charles ^r,s   Bolivar, Hector H ^t   Fischl, Margaret A ^t   Conley, N Jeanne ^u   Olin, Laura ^u   Goldman, Mitchell ^v   Zwickl, Beth ^v   Mildvan, Donna ^w   Garmon, Donald ^w   more..

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g GLAXOSMITHKLINE   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ VircoLab Inc   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

^k UNIVERSITY OF CINCINNATI   (United States)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^m OHIO STATE UNIVERSITY   (United States)

ⁿ GCRC RR00046 ^*

^o SAN FRANCISCO GENERAL HOSPITAL   (United States)

^p VANDERBILT UNIVERSITY   (United States)

^q UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^r NEW YORK UNIVERSITY   (United States)

^s Brigham and Womens Hospital   (United States)

^t UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^u UNIVERSITY OF WASHINGTON   (United States)

^v INDIANA UNIVERSITY   (United States)

^w BETH ISRAEL MEDICAL CENTER   (United States)

^x UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Antiretroviral therapy; Fosamprenavir; Lopinavir; Protease inhibitors; Ritonavir

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ABSCESS; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPID STORAGE; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THRUSH; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENINE; ADOLESCENT; ADULT; CARBAMATES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; PHOSPHORIC ACID ESTERS; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 44949247362     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0902-91     Document Type: Article

References (38)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study: Swiss HIV Cohort Study. Lancet. 1999;353:863-868.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
5. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003;17:1741-1751.
6. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-2199.
7. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002;16:209-218.
8. Lalezari JP, Henry K, O'Hearn M, et al. Enfurvitide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
9. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomized open-label trials. Lancet. 2006;368:466-475.
10. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD, Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007:369:1261-1269.
11. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. International AIDS Society - USA. Topics HIV Med. 2003;11:185-198.
12. Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother. 2004;38:1924-1934.
13. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2001;2:105-113.
14. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53:4-9.
15. Loutfy M, Raboud J, Thompson C, et al. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin Trials. 2003;4:301-310.
16. Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr. 2004;36:921-928.
17. Raguin G, Chene G, Morand-Joubert L, et al. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther. 2004;9:615-625.
18. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combinations with ritonavir? AIDS. 2002;16:296-297.
19. Mauss S, Scholten S, Wolf E, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med. 2004;5:15-17.
20. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004;75:310-323.
21. De Luca A, Baldini F, Cingolani A, et al. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr. 2004;35:359-366.
22. Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48:791-798.
23. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS. 2004;18:1529-1537.
24. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32.
25. Pulido F, Katlama C, Marquez M, et al. A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults. HIV Med. 2004;5:296-302.
26. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
27. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS. 2003;17:1258-1261.
28. Paulsen D, Liao Q, Fusco G, et al. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses. 2002;18;1011-1019.
29. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001;15:609-615.
30. Schmidt B, Korn K, Moschik B, et al. Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother. 2000;44:3213-3216.
31. Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS. 2000;14:1203-1210.
32. Mo H, King MS, King K, et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol. 2005;79:3329-3338.
33. Fumero E, Podzamczer D. New patterns of HIV-1 resistance during HAART. Clin Microbiol Infect. 2003;9:1077-1084.
34. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS. 2003;17:1077-1078.
35. Kashuba ADM, Tierney C, Downey G, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005;19:145-152.
36. Division of AIDS. Table for grading severity of adult adverse experiences, August 1992. Regulatory Compliance Center. Toxicities Tables. Available at: http://66.101.238.59/tox_tables.htm. Accessed October 20, 2006.
37. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS. 2004;18:1503-1511.
38. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282-292.